How Hepatitis B Virus Causes Dermatomyositis
Hepatitis B virus (HBV) triggers dermatomyositis through immune-mediated mechanisms, primarily involving molecular mimicry between HBV antigens and self-proteins, immune complex formation, and tissue damage leading to exposure of intracellular antigens. 1
Pathogenic Mechanisms
The relationship between HBV and dermatomyositis involves several interconnected immunological processes:
Primary Immune Dysregulation
The core mechanism centers on loss of immune tolerance triggered by HBV infection in genetically susceptible individuals. 1 This occurs through three main pathways:
- Molecular mimicry: HBV antigens share structural similarities with self-proteins, causing the immune system to cross-react and attack host muscle and vascular tissues
- Immune complex deposition: Circulating complexes of HBV antigens bound to antibodies deposit in small vessels, triggering complement-mediated vasculopathy 2
- Apoptosis and antigen exposure: Viral-induced tissue damage exposes normally sequestered intracellular antigens to the immune system, breaking tolerance 1
Complement-Mediated Vasculopathy
Dermatomyositis specifically manifests as a complement-mediated vasculopathy of small vessels in muscle tissue. 2 The pathologic cascade includes:
- Deposition of C5b-9 membrane attack complex around microvasculature
- Ischemia and vessel damage leading to perifascicular atrophy
- Mononucular cell infiltrates with B cells, CD4+ T cells, and plasmacytoid dendritic cells in perimysial and perivascular areas 2
Cytokine-Driven Inflammation
The inflammatory milieu is characterized by:
- Type 1 interferons (α/β) and TNF-α as predominant proinflammatory cytokines 2
- IL-4, IL-6, IL-15, and IL-17 contributing to sustained inflammation
- Plasmacytoid dendritic cells producing type 1 interferon in response to viral nucleic acids 2
Clinical Context and Caveats
The association between HBV and dermatomyositis does not always indicate direct viral involvement in muscle tissue. 3 A critical case demonstrated HBV-related liver cirrhosis with dermatomyositis where immunohistochemical staining and fluorescence in situ hybridization were negative for HBsAg, HBcAg, and HBV DNA in muscle tissue 3. This suggests the autoimmune process may be triggered systemically rather than through direct viral invasion of muscle.
Important Pitfalls
- Not all dermatomyositis in HBV patients is causally related - the temporal relationship and exclusion of other triggers must be carefully evaluated 3
- Genetic susceptibility plays a crucial role - family history of autoimmune conditions or hepatocellular carcinoma may indicate increased risk 4
- Viral reactivation risk - immunosuppressive treatment for dermatomyositis can reactivate HBV, creating a treatment paradox 5
Treatment Implications
Antiviral therapy must precede or accompany immunosuppression. 4, 5 The recommended approach includes:
- Screen for HBV before initiating immunosuppressive therapy
- Start entecavir or tenofovir 1-2 weeks before immunosuppression 5
- Combine antiviral therapy with standard dermatomyositis treatment (corticosteroids, methotrexate, or mycophenolate mofetil) 4, 5
- Monitor HBV DNA levels throughout treatment to detect breakthrough reactivation 3
The challenge lies in balancing immunosuppression needed for dermatomyositis against the risk of worsening HBV infection. 5 High-dose methylprednisolone, the mainstay of dermatomyositis treatment, can exacerbate viral replication, making concurrent antiviral coverage essential.